Visium Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Visium Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,397	Closed	-$209K	–	202
2016 Q2	$209K	Sell	5,397 -874,572	-99%	-$31.4M	0.01%	316
2016 Q1	$24.5M	Sell	879,969 -123,344	-12%	-$4.11M	0.42%	53
2015 Q4	$54M	Buy	1,003,313 +12,934	+1%	+$652K	0.81%	20
2015 Q3	$39.7M	Sell	990,379 -61,100	-6%	-$1.99M	0.54%	30
2015 Q2	$33.6M	Buy	1,051,479 +75,060	+8%	+$1.9M	0.48%	38
2015 Q1	$23.3M	Buy	976,419 +275,000	+39%	+$6.16M	0.34%	57
2014 Q4	$12.4M	Buy	701,419 +863	+0.1%	+$13.5K	0.17%	106
2014 Q3	$9.61M	Buy	700,556 +77	+0%	+$1.16K	0.14%	146
2014 Q2	$11.8M	Hold	700,479	–	–	0.18%	107
2014 Q1	$12.7M	Buy	+700,479	New	+$12.6M	0.21%	96

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Visium Asset Management's ITCI Position: Q3 2016 in Review

Visium Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2016, closing a stake of 5,397 shares — an estimated $209K sold.

Visium Asset Management first reported a position in ITCI in Q1 2014 and held it in 10 quarters. The position peaked at $54M in Q4 2015. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

Visium Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2016 after selling out during the quarter.
Visium Asset Management sold 5,397 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $209K.
Visium Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 10 quarters.
Visium Asset Management's Intra-Cellular Therapies Inc. position peaked at $54M in Q4 2015.
131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.